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Abstract 
Background: Sofosbuvir is on the world 
organization’s list of essential medicines, the most 
effective and safe medicines needed in health 
system. It plays a special role in treatment of chronic 
hepatitis C and offers many advantages due to its 
high potency, low side effects, oral administration, 
and high barrier to resistance. 
Objectives: To compare the treatment response in 
treatment naive and treatment experienced chronic 
hepatitis C patients treated with sofosbuvir and 
ribavirin to determine the efficacy of this drug 
combination. 
Methods: In this experimental study 104 chronic 
hepatitis C patients with positive polymerase chain 
reaction (PCR) for hepatitis C virus (HCV) and high 
alanine aminotransferase (ALT) levels were 
included. Out of them 66 (63.5%) were treatment 
naive (received treatment for the first time) and 38 
(36.5%) were treatment experienced. Sofosbuvir 
400mg once a day in combination with ribavirin was 
given for 6 months and treatment responses were 
noted at 4, 12 and 24 weeks. SPSS version 21 was 
used to analyze the data. 
Results: The end treatment response in 104 chronic 
hepatitis C patients was calculated in which 99 
(95.2%) patients responded to the therapy. 63 (95.5%) 
treatment naive patients and 36 (94.7%) treatment 
experienced responded to the therapy. End treatment 
response (ETR) in chronic hepatitis C patients to 
sofosbuvir and ribavirin was irrespective to their 
gender and genotypes and test of significance came 
out as insignificant (p > 0.05). 
Conclusion: Sofosbuvir is effective for both 
treatment naive and treatment experienced chronic 
hepatitis C patients. This regimen is equally 
effective for both genders and all genotypes of 
hepatitis C. 
Keywords: Treatment response, End treatment 
response, Chronic hepatitis C, Sofosbuvir, Ribavirin, 
Genotype. 
Introduction 
Hepatitis C virus (HCV) infection is a major problem 
in the world as there is no vaccine and no post-
exposure prophylaxis to it. It causes cirrhosis and 
hepatocellular carcinoma.1 The global prevalence of 
hepatitis C is 1% as estimated in 2015, which means 
there are 71.1 million cases of hepatitis C in the world.2 
But this prevalence estimates vary widely 
between countries for example 0.3% in England and 
8.5% in Egypt.3 This global estimate of prevalence is 
lower than the previous estimates.2 But prevalence is 
still high in developing countries like Pakistan (6.8%) 
and is still expected to increase in coming years.4 The 
prevalence of HCV calculated in the district Peshawar 
in 2013-2014 is 1.42%.18 A study conducted in Multan 
shows that the prevalence of HCV infections is high in 
diabetic patients as compared to non-diabetic patients. 
It also shows that female diabetics have greater 
prevalence of HCV infections than male diabetics. 
Type 2 diabetes, poverty, urban locality and sharing 
syringes increase the risk of HCV infections.19,20 
 The prevalence of HCV infections is very high in HIV-
infected patients who inject drugs (PWID) in Lahore, 
Pakistan.21 80% Hepatitis C virus infections become 
chronic and out of these 20-30% develop cirrhosis. Old 
immune-compromised males who consume alcohol 
are at greater risk of developing cirrhosis rapidly.22 
There are different genotypes of HCV being 1 and 3 
most common in the world.2 In Pakistan genotype 3a is 
the most prevalent subtype4. Second most frequently 
genotype is genotype 1 in Punjab.24 However, in recent 
years, the frequency of subtype 2a is increased in 
certain geographical sub-regions within Pakistan.4  
Different treatment regimens have been devised for 
chronic hepatitis C.5-13 The regimen including protease 
inhibitor with pegylated interferon alfa-2a (PEG-IFN-
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α) and ribavirin is less effective and has many side 
effects.23 Sofosbuvir, a new drug, is available in 
Pakistan since January 2015, offers many advantages 
due to its high potency, low side effects, oral 
administration, and high barrier to resistance.16,23 
Sofosbuvir is a nucleoside analogue which is 
converted into active nucleotide in the host 
hepatocyte. This active nucleotide competes with the 
natural nucleotide and causes the termination of viral 
RNA replication. Sofosbuvir is effective in all the 
genotypes.17 The End treatment response (ETR) to 
sofosbuvir in relapse HCV patients after renal 
transplant is 97.8%.12 The purpose of this study is to 
compare the treatment response and especially End 
treatment response (ETR) in naive and treatment 
experienced patients of chronic hepatitis C treated 
with sofosbuvir and ribavirin in Pakistani population 
at Gastrointestinal and liver clinics of Rawalpindi. 
Studies conducted before failed to show the end 
treatment response (ETR) in chronic hepatitis C 
patients treated with sofosbuvir and ribavirin with 
respect to naive and treatment experienced patients in 
Pakistani population. This study should help in 
finding the end treatment response to sofosbuvir in 
naive and treatment experienced patients of chronic 
hepatitis C in Rawalpindi region and offer hope to 
many treatment failed patients. 
 
Patients and Methods 
This experimental study was conducted in 
Gastrointestinal and liver clinics of Rawalpindi from 
March 2017 to June 2017. Patients of chronic hepatitis 
C with positive polymerase chain reaction (PCR) for 
hepatitis C virus (HCV) and high alanine 
aminotransferase (ALT) were included in this study 
while patients with chronic liver disease due to causes 
other than hepatitis C were excluded. Non probability 
consecutive sampling technique was used for patient 
inclusion. Sample size of 31 patients was calculated by 
using WHO sample size calculator, keeping level of 
confidence 95%, prevalence in reference study 98%12,27 
and absolute precision 5%. However, we included 104 
chronic hepatitis C patients in this study.  Patients 
were categorized into two groups; treatment naive and 
treatment experienced. Treatment naive were those 
patients who had never undergone any treatment for 
hepatitis C and treatment experienced were patients 
who had previous treatment failures to pegylated 
interferon alfa-2a therapy due to drug resistance, 
virological rebound, drug intolerance, relapse and 
other factors. Sofosbuvir 400mg once a day in 
combination with ribavirin was given to the patients 
for 6 months and treatment responses were noted for 4 
weeks (Rapid virological response RVR), 12 weeks 
(Early virological response EVR) and 24 weeks (End 
treatment response ETR). As this is a retrospective 
study, there was no direct contact between patients 
and researchers so ethical approval was taken from 
head of the hospital. Data was collected and entered in 
SPSS version 21. Frequencies along with percentages 
will be calculated for all categorical data. Whereas 
mean ± standard deviation will be calculated for 
numerical data. Cross tabulation and test of 
significance were also applied. 
 
Results 
One hundred and four patients of chronic hepatitis C 
with positive PCR for HCV were included in this 
study in whom 55 (52.9%) were males and 49 (47.1%) 
were females. The mean age of 104 patients was 
48.20±10.24 years; median 49.50 years and range was 
16-79 years. Among the study participants 66 (63.5%) 
were receiving treatment for the first time (Treatment 
naive) while 38 (36.5%) were treatment experienced. 
Genotype 3A 72 (69.2%) was most frequent genotype 
in study population. Data was taken for 4 weeks, 12 
weeks and 24 weeks, while 24 weeks was end 
treatment response. The treatment response at 4 
weeks, 12 weeks and 24 weeks for both treatment 
naive and treatment experienced is shown in table I.  
63 (95.5%) of treatment naive and 36 (94.7%) of 
treatment experienced were responsive to treatment. 
But test of significance was found to be insignificant (p 
> 0.05).  
End treatment response for both gender and for 
different types of genotypes is given in table II and III 
respectively.  
Table 1: Treatment response at 4 weeks, 12 weeks 
and 24 weeks  
 
Treatment response 
Treatment status 
Total 
N (%) 
 
Chi 
statistic 
P 
value Treatment 
naive N 
(%) 
Treatment 
experienced 
N (%) 
Rapid 
virological 
response 
Positive 4 (8.2%) 3 (11.1%) 7 (9.2%) 
 
0.181 
 
0.671 
(PCR at 4 
weeks) 
Negative 
45 
(91.8%) 
24 (88.9%) 
69 
(90.8%) 
Early 
virological 
response 
Positive 1 (6.7%) 1 (12.5%) 2 (8.7%) 
 
0.224 
 
0.636 
(PCR at 12 
weeks) 
Negative 
14 
(93.3%) 
7 (87.5%) 
21 
(91.3%) 
End 
treatment 
response 
Positive 3 (4.5%) 2 (5.3%) 5 (4.8%) 
 
0.027 
 
0.869 
(PCR at 24 
weeks) 
Negative 
63 
(95.5%) 
36 (94.7%) 
99 
(95.2%) 
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   Figure I: A clustered bar chart displaying the end 
treatment response (PCR at 24 weeks) in treatment 
naive and treatment experienced chronic hepatitis C 
patients (n=104) 
                    
 Table II: End treatment response in males and 
females 
 
Treatment response 
 
 
Gender 
 
 
Total 
N (%) 
 
Chi 
statisti
c 
P value 
Males 
N (%) 
Females 
N (%) 
ETR 
Positiv
e 
2 (3.6%) 3 (6.1%) 5 (4.8%) 
 
0.350 
 
0.554 
(PCR at 24 
weeks) 
Negati
ve 
53 
(96.4%) 
46 (93.9%) 99 (95.2%) 
Total  
55 
(100.0%) 
49 
(100.0%) 
104 
(100.0%) 
53 (96.4%) males and 46 (93.9%) females were 
responsive to the treatment but test of significance was 
found to be insignificant (p >0.05). 
 
 Table III: End treatment response (PCR at 24 weeks) 
in different genotypes                                               
Genotype 
End treatment response 
(PCR at 24 weeks) N (%)  
Total          
N(%) 
 
Chi 
statis
tic 
 
P 
value 
Positive Negative 
Unknown 1 (3.6%) 27 (96.4%) 28 (100.0%)  
0.384 
 
0.984 2A 0 (0.0%) 1 (100.0%) 1 (100.0%) 
3A 4 (5.6%) 68 (94.4%) 72 (100.0%) 
3B 0 (0.0%) 1 (100.0%) 1 (100.0%) 
4 0 (0.0%) 2 (100.0%) 2 (100.0%) 
Total 5 (4.8%) 99 (95.2%) 104 (100.0%) 
  
Test of significance for different genotypes was found 
to be insignificant (p >0.05). 
 
Discussion 
Sofosbuvir is on the world organization’s list of 
essential medicines, the most effective and safe 
medicines needed in health system.25 It plays a special 
role in treatment of chronic hepatitis C and offers 
many advantages due to its high potency, low side 
effects, oral administration, and high barrier to 
resistance.16,23  In this study the treatment response of 
chronic hepatitis C patients to sofosbuvir and ribavirin 
was observed at 4 weeks, 12 weeks and 24 weeks. 
After 4 weeks 45 (91.8%) treatment naive and 24 
(88.9%) treatment experienced chronic hepatitis C 
patients had undetectable viral load which is in 
accordance to the study by Mansoor VB et al showing 
Rapid virological response of 91.58% in naive and 
81.03% in treatment experienced chronic hepatitis C 
patients.26 A study by Akhter TS et al stated 91% 
treatment response in hepatitis C genotype 3 infected 
patients at 4 weeks.27 Rapid virological response (at 4 
weeks) of 91% was observed in a study conducted by 
Irfan M et al on chronic hepatitis C patients treated 
with sofosbuvir and ribavirin.29 
At the end of 12 weeks 14 (93.3%) treatment naive, 7 
(87.5%) treatment experienced and a total of 21 (91.3%) 
chronic hepatitis C patients had undetectable HCV 
viral load. 
A study conducted by Mansoor VB et al found end 
treatment response (at 24 weeks/6 months) of 91 
(95.78%) in naive and 56 (96.55%) in treatment 
experienced chronic hepatitis C patients that is similar 
to current study in which 63 (95.5%) naive and 36 
(94.7%) treatment experienced chronic hepatitis C 
patients were PCR negative for HCV at 24 weeks 
(ETR).26 End treatment response of 61 (93.8%) in naive 
and 51 (100.0%) in treatment experienced hepatitis C 
patients was observed by Akhter TS et al.27 Studies by 
Maria C et al and Satsangi S et al found 100%12 and 
98%28 end of the treatment response in hepatitis C 
patients respectively. A study conducted in Pakistan 
by Irfan M et al which exhibited End of the treatment 
response of 95% in chronic hepatitis C patients.29 
End treatment response in males 53 (96.4%) and 
females 46 (93.9%) was almost same making test of 
significance insignificant (p > 0.05). Study by Mansoor 
VB et al revealed treatment response in 86 (94.5%) 
males and 61 (98.3%) females suffering from hepatitis 
C.26 Similarly study by Akhter TS et al stated treatment 
response of 45 (100.0%) in females and 67 (94.4%)  in 
males with hepatitis C.27 
In this study genotype 2, 3B and 4 had 100% and 
genotype 3A had 94.4% treatment response. This is 
close to a study by by Mansoor VB et al showing 
treatment response in 85.72% genotype 1, 96.5% 
genotype 3 and 100.0% genotype 4 chronic hepatitis C 
patients.26 
 
Conclusion 
Sofosbuvir is effective for both treatment naive and 
treatment experienced chronic hepatitis C patients. 
This regimen is equally effective for both gender and 
all genotypes of hepatitis C. 
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